Syndexa Pharmaceuticals (Watertown, MA) a clinical-stage biopharmaceutical company focused on enzyme inhibitors for Alzheimer’s disease and inflammatory diseases, closed a $8.5M Series B financing. Participants include MP Healthcare Venture Management.